Lifestyle Modification for Erectile Dysfunction in Men With Metabolic Syndrome
LIFE-MetS-ED
Penile Hemodynamic Recovery Following a Six-Month Structured Lifestyle Modification Program in Men With Metabolic Syndrome-Associated Erectile Dysfunction: A Prospective Single-Arm Interventional Study
1 other identifier
interventional
55
0 countries
N/A
Brief Summary
Metabolic syndrome is associated with erectile dysfunction through obesity, insulin resistance, abnormal blood lipids, high blood pressure, and impaired blood-vessel function. This study will evaluate whether a structured six-month lifestyle-modification program can improve penile blood flow and erectile function in men with metabolic syndrome-associated erectile dysfunction. Eligible participants will receive dietary counseling, exercise guidance, weight-management advice, smoking-cessation counseling when applicable, sleep and sedentary-behavior advice, and repeated behavioral reinforcement. Erectile function, penile blood-flow measurements obtained by penile duplex Doppler ultrasonography, body measurements, and selected metabolic laboratory parameters will be assessed before the program and after six months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 6, 2026
CompletedFirst Posted
Study publicly available on registry
August 11, 2026
CompletedStudy Start
First participant enrolled
August 25, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
July 24, 2027
Study Completion
Last participant's last visit for all outcomes
November 24, 2027
August 11, 2026
August 1, 2026
11 months
August 6, 2026
August 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in penile peak systolic velocity from baseline to six months
Change in peak systolic velocity measured in centimeters per second by penile duplex Doppler ultrasonography after intracavernosal vasoactive-agent administration, comparing the baseline value with the six-month post-intervention value.
Baseline and six months after initiation of the lifestyle-modification program.
Secondary Outcomes (5)
Change in erectile-function score
Baseline and six months
Change in end-diastolic velocity
Baseline and six months.
Change in resistive index
Baseline and six months.
Change in body weight
Baseline and six months.
Change in waist circumference
Baseline and six months.
Study Arms (1)
Structured Lifestyle Modification
EXPERIMENTALParticipants will receive a structured six-month lifestyle-modification program consisting of dietary counseling, moderate-intensity physical-activity advice, weight-management counseling, smoking-cessation counseling when applicable, sleep-hygiene advice, reduction of sedentary behavior, and monthly behavioral reinforcement.
Interventions
Participants will receive an initial standardized counseling session followed by written lifestyle instructions and repeated monthly reinforcement. The program will target improved diet quality, reduced caloric intake, increased moderate-intensity aerobic activity, weight reduction according to baseline body mass index and waist circumference, smoking cessation when applicable, improved sleep hygiene, and reduced sedentary behavior. Adherence will be assessed using participant self-report and follow-up review over six months.
Eligibility Criteria
You may qualify if:
- Men aged 30-65 years.
- Erectile dysfunction present for at least six months.
- International Index of Erectile Function-5 score of 21 or less.
- Metabolic syndrome diagnosed according to the International Diabetes Federation criteria.
- Sexually active participants in a stable sexual relationship.
- Willingness and ability to participate in the six-month lifestyle-modification program.
- Ability to provide written informed consent.
You may not qualify if:
- Erectile dysfunction primarily attributable to neurogenic, psychogenic, hormonal, or postsurgical causes.
- Severe hypogonadism requiring immediate testosterone-replacement therapy.
- Use of phosphodiesterase type 5 inhibitors, intracavernosal injections, vacuum erection devices, or other erectile-dysfunction treatment that cannot be discontinued before baseline assessment.
- Significant penile anatomical abnormality that may interfere with penile duplex Doppler assessment, including Peyronie disease.
- Previous pelvic surgery or pelvic radiotherapy likely to affect erectile function.
- Severe or unstable cardiovascular disease that precludes sexual activity or participation in exercise-based lifestyle modification.
- Uncontrolled diabetes mellitus, defined in the protocol as HbA1c greater than 10%.
- Uncontrolled hypertension despite medical therapy.
- Severe renal or hepatic impairment.
- Active malignancy or life expectancy of less than one year.
- Major psychiatric illness, cognitive impairment, or inability to comply with study procedures or follow-up.
- Inability or refusal to provide written informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Abul-fotouh Ahmed, MD
Al-Azhar University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Urology
Study Record Dates
First Submitted
August 6, 2026
First Posted
August 11, 2026
Study Start (Estimated)
August 25, 2026
Primary Completion (Estimated)
July 24, 2027
Study Completion (Estimated)
November 24, 2027
Last Updated
August 11, 2026
Record last verified: 2026-08